Multi-Modal Theragnostic Anticancer Complexes of Rhenium to Circumvent Platinum Resistance in Relapsed Ovarian Cancer
Technical Report,20 Mar 2018,19 Mar 2019
Cornell University Ithaca United States
Pagination or Media Count:
Novel rhenium-based anticancer agents were explored as alternatives to the platinum drugs for the treatment of ovarian cancer. Over the course of this reporting period, we explored the in vivo anticancer activity of one of these promising candidates. These results show that this compound can inhibit ovarian tumor growth in mice. Histopathological analysis further showed that this activity was accompanied by minimal toxic side effects. Additionally, we have developed a new combinatorial synthetic strategy for screening a library of these compounds. These combinatorial efforts have led to the discovery of another promising lead compound that induces necrotic cell death in ovarian cancer cells. Lastly, we have discovered a highly potent rhenium anticancer agent that induces cell death via endoplasmic reticulum ER stress. Given the status of ER dysregulation in cancer cells, this compound represents a promising alternative to conventional platinum-based drugs.
- Medicine and Medical Research